Aurobindo Pharma gets USFDA’s nod for Entecavir Tablets

27 Aug 2015 Evaluate

Aurobindo Pharma has received the final approval from the US Food & Drug Administration (USFDA) to manufacture and market Entecavir Tablets, 0.5mg and 1mg. The approved Abbreviated New Drug Application (ANDA) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Baraclude Tablets, 0.5mg and 1mg, of Bristol-Myers Squibb.

Entecavir Tablets are indicated for treatment of chronic hepatitis B virus infection of the liver. The product has an estimated market size of $294 million for the twelve months ending June 2015.

This is the 44th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 209 ANDA approvals (181 Final approvals including 9 from Aurolife Pharma LLC and 28 Tentative approvals) from USFDA.

Aurobindo Pharma Share Price

1173.95 1.65 (0.14%)
19-Jan-2026 13:26 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1676.45
Dr. Reddys Lab 1173.30
Cipla 1392.60
Zydus Lifesciences 870.00
Lupin 2177.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×